KRAS and non-small cell lung carcinoma: We elected to designate KRAS G12C as the reference cohort for our study as it is one of the most prevalent mutations in NSCLC, and its prognostic and predictive properties have been well characterized in the adjuvant setting.15, , –18 Five-year RFS and OS results in the current study are similar to those reported by the LACE-Bio group for KRAS, thus confirming the interpretation and applicability of our study findings.17